Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
Richard Bruce WarrenMark G LebwohlHoward SofenVincent PiguetMatthias AugustinF Brocknull C ArendtF FierensAndrew BlauveltPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2021)
Response to CZP was durable over three years; no new safety signals were identified.